{"id":335985,"date":"2019-07-07T02:00:00","date_gmt":"2019-07-07T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/less-hypoglycemia-with-insulin-glargine-300-e-ml\/"},"modified":"2019-07-07T02:00:00","modified_gmt":"2019-07-07T00:00:00","slug":"less-hypoglycemia-with-insulin-glargine-300-e-ml","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/less-hypoglycemia-with-insulin-glargine-300-e-ml\/","title":{"rendered":"Less hypoglycemia with insulin glargine 300 E\/ml"},"content":{"rendered":"<p><strong>The altered pharmacokinetics and dynamics of the drug are associated with a reduced risk of hypoglycemia.<\/strong><\/p>\n<p><!--more--><\/p>\n<p>Fear of hypoglycemia can severely affect both quality of life and treatment adherence and persistence in patients with type 2 diabetes. It stands in the way of achieving individual blood glucose levels, especially when patients have already experienced severe hypoglycemia. The risk of hypoglycemia can be reduced with <sup>Toujeo\u00ae<\/sup> (insulin glargine 300&nbsp;E\/ml), as some studies show.<\/p>\n<h2 id=\"less-hypoglycemia-thanks-to-revised-formulation\">Less hypoglycemia thanks to revised formulation<\/h2>\n<p>Clinical benefits from the altered pharmacokinetics and dynamics of insulin glargine 300&nbsp;E\/ml versus insulin glargine 100&nbsp;E\/ml are evident from the EDITION study data. For example, the meta-analysis of one-year data (EDITION 1 to 3) concluded that patients with type 2 diabetes of different stages benefited from insulin glargine 300 E\/ml, which was not only more effective in lowering HbA1c compared with insulin glargine 100 E\/ml, but was also associated with less hypoglycemia: The rate of nocturnal confirmed hypoglycemia decreased by 25%, and the risk at any time of day decreased by 9%. Subgroup analyses confirm these results. For example, patients with type 2 diabetes and renal dysfunction also benefited from the reduced risk of hypoglycemia.<\/p>\n<h2 id=\"favorable-profile-also-in-older-patients\">Favorable profile also in older patients<\/h2>\n<p>The current SENIOR study also confirms significant superiority of insulin glargine 300 E\/ml over insulin glargine 100 E\/ml. The prospective, randomized, controlled, parallel-group study compared two groups of a total of 1000 elderly patients with type 2 diabetes. The minimum age was 65 years. While one group received insulin glargine 100&nbsp;E\/ml, the other received insulin glargine 300&nbsp;E\/ml. After 26 weeks, insulin glargine 300 E\/ml was shown to be equally effective in lowering HbA1c, but carried a lower risk of symptomatic hypoglycemia. This finding could be clinically relevant, especially since the SENIOR study population is significantly more vulnerable to younger patients.<\/p>\n<h2 id=\"insulin-glargine-300-e-ml-versus-insulin-degludec\">Insulin glargine 300 E\/ml versus insulin degludec<\/h2>\n<p>The BRIGHT study is the first head-to-head randomized controlled trial directly comparing the effect of insulin glargine 300 E\/ml and insulin degludec in insulin-na\u00efve type 2 diabetic patients. Study participants were randomized into two groups, one receiving insulin glargine 300&nbsp;E\/ml (n=466) and the other insulin degludec (n=463) as an evening dose. Throughout the 24-week study period and during the maintenance period, the incidence and frequency of confirmed hypoglycemic events were comparable between the two basal insulins. However, in the titration phase (weeks 0 to 12), administration of insulin glargine 300&nbsp;E\/ml versus insulin degludec was associated with a reduction in confirmed hypoglycemia at any time of day.<\/p>\n<p>&nbsp;<\/p>\n<p><em>Source: Sanofi<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>HAUSARZT PRAXIS 2019; 14(6): 29<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The altered pharmacokinetics and dynamics of the drug are associated with a reduced risk of hypoglycemia.<\/p>\n","protected":false},"author":7,"featured_media":89516,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Type 2 diabetes","footnotes":""},"category":[11384,11297,11530,11323,11548,11503],"tags":[11655,28437,28442,28436],"powerkit_post_featured":[],"class_list":["post-335985","post","type-post","status-publish","format-standard","has-post-thumbnail","category-endocrinology-and-diabetology","category-general-internal-medicine","category-market-medicine","category-partner-content-en","category-rx-en","category-studies","tag-diabetes-en","tag-glargine","tag-hypoglycemia-en","tag-sanofi-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-13 20:41:53","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":335999,"slug":"moins-dhypoglycemie-sous-insuline-glargine-300-u-ml","post_title":"Moins d'hypoglyc\u00e9mie sous insuline glargine 300 U\/ml","href":"https:\/\/medizinonline.com\/fr\/moins-dhypoglycemie-sous-insuline-glargine-300-u-ml\/"},"it_IT":{"locale":"it_IT","id":336011,"slug":"meno-ipoglicemia-con-linsulina-glargine-300-e-ml","post_title":"Meno ipoglicemia con l'insulina glargine 300 E\/ml","href":"https:\/\/medizinonline.com\/it\/meno-ipoglicemia-con-linsulina-glargine-300-e-ml\/"},"pt_PT":{"locale":"pt_PT","id":336018,"slug":"menos-hipoglicemia-com-glargina-de-insulina-300-e-ml","post_title":"Menos hipoglic\u00e9mia com glargina de insulina 300 E\/ml","href":"https:\/\/medizinonline.com\/pt-pt\/menos-hipoglicemia-com-glargina-de-insulina-300-e-ml\/"},"es_ES":{"locale":"es_ES","id":336023,"slug":"menos-hipoglucemia-con-insulina-glargina-300-e-ml","post_title":"Menos hipoglucemia con insulina glargina 300 E\/ml","href":"https:\/\/medizinonline.com\/es\/menos-hipoglucemia-con-insulina-glargina-300-e-ml\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/335985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=335985"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/335985\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/89516"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=335985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=335985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=335985"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=335985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}